Can a nasal spray calm public speaking nerves? new study investigates
NCT ID NCT05011396
First seen Dec 26, 2025 · Last updated Apr 29, 2026 · Updated 17 times
Summary
This study tested a nasal spray called PH94B to see if it could quickly reduce anxiety in adults with social anxiety disorder during a public speaking challenge. About 228 participants were asked to give a short speech after using the spray or a placebo. The trial was stopped early, but it aimed to find a fast-acting, non-sedating option for managing sudden anxiety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOCIAL ANXIETY DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
VistaGen Clinical Center
Allentown, Pennsylvania, 18104, United States
-
VistaGen Clinical Site
Phoenix, Arizona, 85012, United States
-
VistaGen Clinical Site
Garden Grove, California, 92845, United States
-
VistaGen Clinical Site
Oceanside, California, 92056, United States
-
VistaGen Clinical Site
Temecula, California, 92591, United States
-
VistaGen Clinical Site
Alpharetta, Georgia, 30022, United States
-
VistaGen Clinical Site
Prairie Village, Kansas, 66208, United States
-
VistaGen Clinical Site
Boston, Massachusetts, 02131, United States
-
VistaGen Clinical Site
Flowood, Mississippi, 39232, United States
-
VistaGen Clinical Site
Berlin, New Jersey, 08009, United States
-
VistaGen Clinical Site
Brooklyn, New York, 11235, United States
-
VistaGen Clinical Site
New York, New York, 10032, United States
-
VistaGen Clinical Site
Rochester, New York, 14618, United States
-
VistaGen Clinical Site
Memphis, Tennessee, 38119, United States
-
VistaGen Clinical Site
Austin, Texas, 78737, United States
Conditions
Explore the condition pages connected to this study.